Arcturus Therapeutics Holdings Inc. (ARCT) Earnings Call Transcripts
Arcturus Therapeutics Holdings Inc.'s Latest Earnings Call - June 5, 2026
The Arcturus Therapeutics Holdings Inc. annual meeting on June 5, 2026, primarily focused on administrative matters, including board elections and executive compensation approvals. No financial results or guidance updates were provided during this meeting, which is typical for an annual stockholder meeting rather than an earnings call. The meeting successfully achieved a quorum with approximately 75.4% of shares represented, and all proposals, including the election of directors and the approval of executive compensation, were passed.
Reported metrics
| Metric | Value |
|---|---|
| Quorum Percentage | 75.4% (inline) |
| Votes for Executive Compensation | 15,254,240 (inline) |
| Votes for Deloitte & Touche Ratification | 21,378,017 (inline) |
| Total Shares Outstanding | 28,423,069 (neutral) |
What management said
A list of stockholders is open for inspection by any stockholder participating in this meeting and is available on the virtual meeting website. Continental Stock Transfer & Trust Company has also certified that each stockholder entitled to vote at this meeting has been sent a notice of this meeting. The initial order of business is to determine the presence of a quorum pursuant to action taken by the Board of Directo...
I hereby determine that the number of votes represented at this meeting in person or by proxy constitutes a quorum for the conduct of business at this meeting. The first matter to be voted on today is the election of Dr. Peter Farrell; myself, Joseph E. Payne, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, Dr. John Markels, and Dr. Moncef Slaoui to the Board of Directors as set forth more...
What analysts pressed on
Analysts did not raise specific concerns during this meeting as it was focused on procedural matters rather than financial performance or strategic guidance.
Main topics on the call
- Board of Directors Election — The election of Dr. Peter Farrell, Joseph E. Payne, and others to the Board of Directors was approved. Each nominee received more than one vote in favor, meeting the plurality requirement.
- Executive Compensation Approval — The advisory vote on executive compensation was approved with 15,254,240 votes in favor, exceeding the majority requirement.
- Appointment of Deloitte & Touche — The ratification of Deloitte & Touche, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was approved with 21,378,017 votes in favor.
- Quorum Achievement — The meeting achieved a quorum with 21,435,189 votes present, representing approximately 75.4% of outstanding shares.
Read the full Arcturus Therapeutics Holdings Inc. transcript (June 5, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (ARCT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 48 calls on record spanning March 11, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 48 Arcturus Therapeutics Holdings Inc. earnings call transcripts on record, spanning March 11, 2020 to August 6, 2026. Based on this history, Arcturus Therapeutics Holdings Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ARCT
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 48
- First call
- March 11, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly